| Bioactivity | alpha-Asarone (α-Asarone) is one of the main psychoactive compounds, and possesses an antidepressant-like activity in mice. | ||||||||||||
| Invitro | The results indicated that α-asarone significantly attenuated the LPS-stimulated increase in neuroinflammatory responses and suppressed pro-inflammatory cytokine production in BV-2 cells. Mechanistic study revealed that alpha-Asarone (α-Asarone) inhibited the LPS-stimulated activation via regulation of nuclear factor kappa-B by blocking degradation of inhibitor kappa B-alpha signaling in BV-2 microglial cells[2]. | ||||||||||||
| In Vivo | The present results reveal that the acute treatment of alpha-Asarone (α-Asarone) elicited biphasic responses on immobility such that the duration of the immobility time is significantly reduced at lower doses (15 and 20 mg/kg, i.p.) but increased at higher doses (50 and 100 mg/kg, i.p.) in the TST. Besides, alpha-Asarone (α-Asarone) at higher doses (50 and 100 mg/kg, i.p.) significantly decreased the spontaneous locomotor activity[1]. | ||||||||||||
| Name | alpha-Asarone | ||||||||||||
| CAS | 2883-98-9 | ||||||||||||
| Formula | C12H16O3 | ||||||||||||
| Molar Mass | 208.25 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Ranjithkumar Chellian, et al. Biphasic Effects of α-Asarone on Immobility in the Tail Suspension Test: Evidence for the Involvement of the Noradrenergic and Serotonergic Systems in Its Antidepressant-Like Activity. Front Pharmacol. 2016; 7: 72. [2]. Byung-Wook Kim, et al. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease. Neuropharmacology, Volume 97, October 2015, Pages 46–57 [3]. Hye-Jung Park, et al. Effect of α-asarone on angiogenesis and matrix metalloproteinase. Environmental Toxicology and Pharmacology, Volume 39, Issue 3, May 2015, Pages 1107–1114 |